Is topiramate a potential therapeutic agent for cerebral hypoxic/ischemic injury?

Experimental Neurology

Volumn 203, Issue 1, 2007, Pages 5-7

  Choi, Ji Woong ^a   Kim, Won Ki ^a  

^a Ewha Womans University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AMPA RECEPTOR; CALCIUM; DIZOCILPINE; GLUTAMATE RECEPTOR; KAINIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; RECEPTOR SUBTYPE; RECEPTOR SUBUNIT; TOPIRAMATE;

ARTICLE; BRAIN HYPOXIA; BRAIN INFARCTION SIZE; BRAIN INJURY; BRAIN ISCHEMIA; BRAIN MITOCHONDRION; BRAIN OXYGEN CONSUMPTION; BRAIN PERFUSION; BRAIN PROTECTION; CALCIUM CURRENT; CELL CYCLE PROGRESSION; CELL DEATH; CELLULAR DISTRIBUTION; CYTOTOXICITY; DRUG ACTIVITY; DRUG INHIBITION; DRUG TREATMENT FAILURE; ENZYME INHIBITION; NERVE CELL CULTURE; NEUROPROTECTION; NEWBORN HYPOXIA; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; THERAPY DELAY; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 33751422575     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2006.09.014     Document Type: Note

References (33)

1. Angehagen M., Ben-Menachem E., Ronnback L., and Hansson E. TPM protects against glutamate- and kainate-induced neurotoxicity in primary neuronal-astroglial cultures. Epilepsy Res. 54 (2003) 63-71
2. Angehagen M., Ronnback L., Hansson E., and Ben-Menachem E. Topiramate reduces AMPA-induced Ca(2+) transients and inhibits GluR1 subunit phosphorylation in astrocytes from primary cultures. J. Neurochem. 94 (2005) 1124-1130
3. Astrup A., and Toubro S. Topiramate: a new potential pharmacological treatment for obesity. Obes. Res. 12 (2004) 167S-173S
4. Costa C., Martella G., Picconi B., Prosperetti C., Pisani A., Di Filippo M., Pisani F., Bernardi G., and Calabresi P. Multiple mechanisms underlying the neuroprotective effects of antiepileptic drugs against in vitro ischemia. Stroke 37 (2006) 1319-1326
5. D'Amico D., Grazzi L., Usai S., Moschiano F., and Bussone G. Topiramate in migraine prophylaxis. Neurol. Sci. 26 Suppl 2 (2005) s130-s133
6. Dirnagl U., Ladecola C., and Moskowitz M.A. Pathobiology of ischemic stroke; an integrated view. Trends Neurosci. 22 (1999) 391-397
7. Dodgson S.J., Shank R.P., and Maryanoff B.E. Topiramate as an inhibitor of carbonic anhydrase isoenzymes. Epilepsia 41 Suppl. 1 (2000) S35-S39
8. Edmonds Jr. H.L., Jiang Y.D., Zhang P.Y., and Shank R. TPM as a neuroprotectant in a rat model of global ischemia-induced neurodegeneration. Life Sci. 69 (2001) 2265-2277
9. Follett P.L., Deng W., Dai W., Talos D.M., Massillon L.J., Rosenberg P.A., Volpe J.J., and Jensen F.E. Glutamate receptor-mediated oligodendrocyte toxicity in periventricular leukomalacia: a protective role for topiramate. J. Neurosci. 24 (2004) 4412-4420
10. Giulian D., and Vaca K. Inflammatory glia mediate delayed neuronal damage after ischemia in the central nervous system. Stroke 24 (1993) 184-190
11. Guerrini R., and Pameggiani L. Topiramate and its clinical applications in epilepsy. Expert Opin. Pharmacother. 7 (2006) 811-823
12. Hallenbeck J.M., Dutka A.J., Tanishima T., Kochanek P.M., Kamaroo K.K., Thompson C.B., Obrenovitch T.P., and Contreras T.J. Polymorphonuclear leukocyte accumulation in brain regions with low blood flow during the early postischemic period. Stroke 17 (1986) 246-253
13. Heuschmann P.U., Berger K., Misselwitz B., Hermanek P., Leffmann C., Adelmann M., Buecker-Nott H.J., Rother J., Neundoerfer B., Kolominsky-Rabas P.L., and for the German Stroke Registers Study Group and for the Competence Net Stroke. Frequency of thrombolytic therapy in patients with acute ischemic stroke and the risk of in-hospital mortality: the German Stroke Registers Study Group. Stoke 34 (2003) 1106-1113
14. Heuschmann P.U., Kolominsky-Rabas P.L., Rother J., Misselwitz B., Lowitzsch K., Heidrich J., Hermanek P., Leffmann C., Sitzer M., Biegler M., Buecker-Nott H.J., Berger K., and for the German Stroke Registers Study Group. Predictors of in-hospital mortality in patients with acute ischemic stroke treated with thrombolytic therapy. J. Am. Med. Assoc. 292 (2004) 1831-1838
15. Ikonomidou C., Mosinger J.L., Salles K.S., Labruyere J., and Olney J.W. Sensitivity of the developing rat brain to hypobaric/ischemic damage parallels sensitivity to N-methyl-aspartate neurotoxicity. J. Neurosci. 9 (1989) 2809-2818
16. Jakowec M.W., Jackson-Lewis V., Chen X., Langston J.W., and Przedborski S. The postnatal development of AMPA receptor subunits in the basal ganglia of the rat. Dev. Neurosci. 20 (1998) 19-33
17. Johnston M.V., Trescher W.H., Ishida A., and Nakajima W. Neurobiology of hypoxic-ischemic injury in the developing brain. Pediatr. Res. 49 (2001) 735-741
18. Kaminski R.M., Banerjee M., and Rogawski M.A. Topiramate selectively protects against seizures induced by ATPA, a GluR5 kainate receptor agonist. Neuropharmacology 46 (2004) 1097-1104
19. Kudin A.P., Debska-Vielhaber G., Vielhaber S., Elger C.E., and Kunz W.S. The mechanism of neuroprotection by topiramate in an animal model of epilepsy. Epilepsia 45 (2004) 1478-1487
20. Lee S.R., Kim S.P., and Kim J.E. Protective effect of topiramate against hippocampal neuronal damage after global ischemia in the gerbils. Neurosci. Lett. 281 (2000) 183-186
21. Lees G.J. The possible contribution of microglia and macrophages to delayed neuronal death after ischemia. J. Neurol. Sci. 114 (1993) 119-122
22. Lipton P. Ischemic cell death in brain neurons. Physiol. Rev. 79 (1999) 1451-1568
23. Liu Y., Barks J.D., Xu G., and Silverstein F.S. TPM extends the therapeutic window for hypothermia-mediated neuroprotection after stroke in neonatal rats. Stroke 35 (2004) 1460-1465
24. Margaill I., Plotkine M., and Lerouet D. Antioxidant strategies in the treatment of stroke. Free Radical Biol. Med. 39 (2005) 429-443
25. Monyer H., Burnashev N., Laurie D.J., Sakmann B., and Seeburg P.H. Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. Neuron 12 (1994) 529-540
26. Muir K.W., and Lees K.R. Excitatory amino acid antagonists for acute stroke. Cochrane Database Syst. Rev. 3 (2003) CD001244
27. Schubert S., Brandl U., Brodhun M., Ulrich C., Spaltmann J., Fiedler N., and Bauer R. Neuroprotective effects of topiramate after hypoxia-ischemia in newborn piglets. Brain Res. 1058 (2005) 129-136
28. Sfaello I., Baud O., Arzimanoglou A., and Gressens P. Topiramate prevents excitotoxic damage in the newborn rodent brain. Neurobiol. Dis. 20 (2005) 837-848
29. Shank R.P., Gardocki J.F., Streeter A.J., and Maryanoff B.E. An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics and mechanism of action. Epilepsia 41 (2000) S3-S9
30. White H.S., Brown S.D., Woodhead J.H., Skeen G.A., and Wolf H.H. Topiramate enhances GABA-mediated chloride flux and GABA-evoked chloride currents in murine brain neurons and increases seizure threshold. Epilepsy Res. 28 (1997) 167-179
31. Yang Y., Shuaib A., Li Q., and Siddiqui M.M. Neuroprotection by delayed administration of TPM in a rat model of middle cerebral artery embolization. Brain Res. 804 (1998) 169-176
32. Yoneda S., Tanaka E., Goto W., Ota T., and Hara H. Topiramate reduces excitotoxic and ischemic injury in the rat retina. Brain Res. 967 (2003) 257-266
33. Zona C., Ciotti M.T., and Avoli M. Topiramate attenuates voltage-gated sodium currents in rat cerebellar granule cells. Neurosci. Lett. 231 (1997) 123-126